Key Takeaways from CAPItello-291 in HR+ Breast Cancer
Following a comprehensive review of CAPItello-291, Rohit Gosain, MD, and Rahul Gosain, MD, provide closing thoughts on key takeaways.
Adverse Event Data from CAPItello-291 in HR+ Breast Cancer
Focusing on the safety profile, the Oncology Brothers and Hope Rugo, MD, review safety data from CAPItello-291 and discuss adverse event management practices for patients with breast cancer.
Key Data from CAPItello-291 in HR+ Breast Cancer
Hope Rugo, MD, reviews key data from CAPItello-291 on capivasertib in patients with HR+ breast cancer, highlighting progression-free survival and overall survival.
Biomarker Testing and Prevalence of AKT1/PIK3CA/PTEN Mutations in Breast Cancer
Medical oncologists provide insights on biomarker testing and the prevalence of AKT1, PIK3CA, and PTEN mutations in breast cancer.
Rationale and Study Design of CAPItello-291 in HR+ Advanced Breast Cancer
Hope Rugo, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the rationale and study design for CAPItello-291 in HR+ advanced breast cancer.
Key Takeaways from SABCS 2023
Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in HR+/HER2- breast cancer.
TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer
Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.
Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer
Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.
MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer
Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.
Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer
Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.
PFS Improvement Seen With Capivasertib/Fulvestrant in HR+/HER2- Breast Cancer
Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.
HR+/HER2 Metastatic Breast Cancer: Future Directions in Care
Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.
Selecting Optimal Second- and Third-Line Therapy for HR+/HER2- mBC
Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.
Elacestrant Therapy in HR+/HER2- Metastatic Breast Cancer: The EMERALD Trial
Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.
Treatment Options for HR+/HER2- Metastatic Breast Cancer with Disease Progression on Standard-of-Care Therapy
A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.
The Role of ESR1 Mutations and Approaches to Biomarker Testing in Endocrine-Resistant Breast Cancer
Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.
Case Overview: A 57-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer
Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).
Clinical Pearls for Treating Patients With Metastatic TNBC
Hope Rugo, MD, provides insights on best practices for managing metastatic TNBC in community settings.
Immune-Related Adverse Effects of ICI Therapies in Metastatic TNBC
An expert explains the different types of immune-related adverse effects associated with the use of immune checkpoint inhibitors.
Germline BRCA1/2 Mutations in Metastatic TNBC
Dr Hope Rugo discusses the importance of testing for germline BRCA1/2 mutations in patients with triple-negative breast cancer.
IMpassion130 and KEYNOTE-355 Trials in Patients With Metastatic TNBC: Part 2
Hope Rugo, MD, continues to discuss key clinical trials affecting metastatic triple-negative breast cancer, including IMpassion131.
IMpassion130 and KEYNOTE-355 Trials in Patients With Metastatic TNBC: Part 1
An expert in breast oncology discusses the IMpassion130 and KEYNOTE-355 clinical trials.
Early Stage Options for Patients With Metastatic TNBC
Dr Rugo educates on early stage treatment options and molecular testing guidelines for patients with metastatic triple-negative breast cancer.
Metastatic TNBC Case Overview
Hope Rugo, MD, discusses the case of a 49-year-old woman diagnosed with metastatic triple-negative breast cancer.
KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast Cancer
Hope S. Rugo, MD, discusses the potential role of immunotherapy for the treatment of patients with triple-negative breast cancer (TNBC), based on data from the KEYNOTE-522 clinical trial. Immunotherapy has been very exciting in this setting.
Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC
Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
5-Year Follow-Up of CALGB 40502 Study in TNBC
Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).
Exploring Extended Adjuvant Endocrine Therapy for HR+ Breast Cancer
Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.
Differentiating Factors of Abemaciclib Among the CDK 4/6 Inhibitors for Breast Cancer
Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.
Phase II Results for Abemaciclib in Pretreated HR+/HER2-Negative Breast Cancer
Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.
2 Commerce Drive Cranbury, NJ 08512